

Carola Rong

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3069764/publications.pdf>

Version: 2024-02-01

21
papers

748
citations

759233

12
h-index

794594

19
g-index

21
all docs

21
docs citations

21
times ranked

1303
citing authors

#	ARTICLE	IF	CITATIONS
1	13-Month maintenance ECT treatment in a 66-year-old male patient with pacemaker. , 2022, 1, 100005.		0
2	The role of lithium treatment on comorbid anxiety symptoms in patients with bipolar depression. Journal of Affective Disorders, 2022, 308, 71-75.	4.1	4
3	Ecological momentary assessment of depressive symptoms using the mind.me application: Convergence with the Patient Health Questionnaire-9 (PHQ-9). Journal of Psychiatric Research, 2021, 135, 311-317.	3.1	15
4	A Novel Refractory Mood Disorders and Electroconvulsive Therapy Elective for Medical Students: Fighting Stigma through Experience. Psychiatric Quarterly, 2021, 92, 1541-1548.	2.1	1
5	A case of mirror image agnosia and mirrored self-misidentification syndrome in schizophrenia without dementia or structural abnormalities. Neurocase, 2020, 26, 317-319.	0.6	1
6	Intracellular Signaling Cascades in Bipolar Disorder. Current Topics in Behavioral Neurosciences, 2020, 48, 101-132.	1.7	9
7	Does obesity and diabetes mellitus metastasize to the brain? "Metaboptosis" and implications for drug discovery and development. CNS Spectrums, 2019, 24, 467-469.	1.2	5
8	Serum metabolic profiling using small molecular water-soluble metabolites in individuals with schizophrenia: A longitudinal study using a pre-post treatment design. Psychiatry and Clinical Neurosciences, 2019, 73, 100-108.	1.8	20
9	Rapastinel - an investigational NMDA-R modulator for major depressive disorder: evidence to date. Expert Opinion on Investigational Drugs, 2019, 28, 113-119.	4.1	20
10	Cognitive impairment in major depressive disorder. CNS Spectrums, 2019, 24, 22-29.	1.2	125
11	Pharmacodynamic and pharmacokinetic evaluation of buprenorphine + samidorphan for the treatment of major depressive disorder. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 475-482.	3.3	12
12	The use of brexpiprazole amongst individuals with insufficient outcomes with aripiprazole or bupropion: A case series. Perspectives in Psychiatric Care, 2018, 54, 507-513.	1.9	9
13	Drug-drug interactions as a result of co-administering Δ^9 -THC and CBD with other psychotropic agents. Expert Opinion on Drug Safety, 2018, 17, 51-54.	2.4	64
14	Pharmacological Treatment of Cognitive Symptoms in Major Depressive Disorder. CNS and Neurological Disorders - Drug Targets, 2018, 16, 891-899.	1.4	18
15	Recognition and Treatment of Cognitive Dysfunction in Major Depressive Disorder. Frontiers in Psychiatry, 2018, 9, 655.	2.6	150
16	Predictors of Response to Ketamine in Treatment Resistant Major Depressive Disorder and Bipolar Disorder. International Journal of Environmental Research and Public Health, 2018, 15, 771.	2.6	80
17	Cognitive impairment as measured by the THINC-integrated tool (THINC-it): The association with self-reported anxiety in Major Depressive Disorder. Journal of Affective Disorders, 2018, 238, 228-232.	4.1	11
18	Therapeutic potential of JAK/STAT pathway modulation in mood disorders. Reviews in the Neurosciences, 2018, 30, 1-7.	2.9	35

#	ARTICLE	IF	CITATIONS
19	Determinants of cognitive function in individuals with type 2 diabetes mellitus: A meta-analysis. <i>Annals of Clinical Psychiatry</i> , 2018, 30, 38-50.	0.6	28
20	Cannabidiol in medical marijuana: Research vistas and potential opportunities. <i>Pharmacological Research</i> , 2017, 121, 213-218.	7.1	102
21	Cognitive impairment as measured by the THINC-integrated tool (THINC-it): Association with psychosocial function in major depressive disorder. <i>Journal of Affective Disorders</i> , 2017, 222, 14-20.	4.1	39